Companies · ATR
AptarGroup
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Oct 30, 2026
Aptar Q3 2026: Pharma pipeline acceleration offsets beauty margin pressure; emergency medicine destocking laps in Q4.
Aptar delivered 5% core sales growth across all three segments in Q3 2026, with Pharma showing 8% underlying growth ex-emergency medicine and Injectables posting its sixth consecutive high-single-digit quarter. Adjusted EBITDA margin contracted 190 basis points year-over-year to 21.3%, driven by the anticipated $65M naloxone destocking headwind and persistent North American Beauty operational challenges that CEO Gael Touya signaled will require multi-quarter transformation rather than quick remediation. The company raised its Q4 2026 adjusted EPS guidance to $1.39–$1.47 (17% growth at midpoint), expecting emergency medicine headwind to fully lap and Pharma margins to recover as productivity initiatives gain traction.
Tone: cautiousRevenue
$3.8B
ATR 10-K · FY 2025
Employees
14,000
Revenue FY2024
$3.6B
EBITDA margin
21.3%
Profile
ATR 10-K Item 1 · Feb 6, 2026AptarGroup is a global leader in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies, serving pharmaceutical, beauty, personal care, food, and beverage markets. The company operates three reporting segments — Pharma, Beauty, and Closures — across approximately 20 countries with roughly 14,000 employees. Aptar differentiates through proprietary material science, clean-room manufacturing, digital health solutions, and a broad portfolio of dispensing pumps, aerosol valves, elastomeric components, and active material science innovations.
Read filing description ↓ Collapse description ↑
Aptar is a global leader in the design and manufacturing of drug and consumer product dosing, dispensing and protection technologies. Aptar serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care and home care. Using proprietary design, engineering, materials science, and manufacturing capabilities, Aptar supports customers across these end markets by enabling safe, functional, and differentiated product and service delivery. Aptar is headquartered in Crystal Lake, Illinois and has approximately 14,000 employees in approximately 20 different countries. Our business was started in the late 1940's, manufacturing and selling aerosol valves in the United States, and has grown through acquisitions and organic growth. We have manufacturing facilities located throughout the world including North America, Europe, Asia and Latin America. We have approximately 5,000 customers with no single customer or group of affiliated customers accounting for greater than 4% of our 2025 Net Sales. Our primary products are dispensing pumps, closures, aerosol valves, elastomeric primary packaging components, active material science solutions and digital health solutions. We are organized into three reporting segments: Pharma (approximately 46% of Net Sales), Beauty (approximately 35% of Net Sales), and Closures (approximately 19% of Net Sales). We partner with our customers by providing innovative solutions and end market expertise, and we design our products with both people and the environment in mind.
Primary products
- dispensing pumps
- closures
- aerosol valves
- elastomeric primary packaging components
- active material science solutions
- digital health solutions
Business segments
End markets
Geographies
Named customers
We have approximately 5,000 customers with no single customer or group of affiliated customers accounting for greater than 4% of our 2025 Net Sales.
“We believe our competitive advantages include our consistent high levels of innovation, quality, regulatory, pharma services, geographic diversity, financial strength and reliability and breadth of products and services.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Reported net sales increased 5% to $3.78 billion in 2025 from $3.58 billion in 2024, driven by a 2% positive currency translation impact, a 1% contribution from acquisitions, and 2% core sales growth.
The rest of ATR is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.